Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8
3 clinical trials · Condition
◉ Watch Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8
| Record | Firm | Date |
|---|---|---|
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer (NCT06959641) | Jochen Lorch | 2025-06-06 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer (NCT04061980) | Providence Health & Services | 2020-10-30 |
Track Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 automatically
Every clearance here is in the API, with alerts when new ones post.